MA29681B1 - Formes galeniques du risedronate - Google Patents
Formes galeniques du risedronateInfo
- Publication number
- MA29681B1 MA29681B1 MA30333A MA30333A MA29681B1 MA 29681 B1 MA29681 B1 MA 29681B1 MA 30333 A MA30333 A MA 30333A MA 30333 A MA30333 A MA 30333A MA 29681 B1 MA29681 B1 MA 29681B1
- Authority
- MA
- Morocco
- Prior art keywords
- risedronate
- chelating agent
- small intestine
- bisphosphonate
- food
- Prior art date
Links
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 title abstract 6
- 229940089617 risedronate Drugs 0.000 title abstract 6
- 229940122361 Bisphosphonate Drugs 0.000 abstract 4
- 150000004663 bisphosphonates Chemical class 0.000 abstract 4
- 239000002738 chelating agent Substances 0.000 abstract 3
- 235000013305 food Nutrition 0.000 abstract 3
- 210000000813 small intestine Anatomy 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
Des formes galéniques à administration orale de risedronate constituées d'une préparation pharmaceutique comprenant une quantité sûre et efficace du risedronate, d'un agent chélatant, et de substances destinées à libérer le risedronate et l'agent chélatant de façon retardée dans l'intestin grêle, permettent la libération immédiate de la préparation pharmaceutique dans l'intestin grêle du sujet mammifère et une absorption pharmaceutiquement efficace du bisphosphonate avec ou sans aliments ou boissons. La présente invention diminue de façon substantielle l'interaction entre le risedronate et les aliments ou boissons, ladite interaction résultant en la non-disponibilité du principe actif de type bisphosphonate pour l'absorption. La forme galénique résultante peut ainsi être prise avec ou sans aliments. En outre, la présente invention permet la libération du risedronate et de l'agent chélatant au niveau de l'intestin grêle, ce qui soulage de façon substantielle l'irritation de l'appareil gastro¬intestinal supérieur associée aux thérapies employant des bisphosphonates. Ces avantages permettent de simplifier les régimes de traitement complexes existants et peuvent amener à une amélioration de l'observance des thérapies à base de bisphosphonates par le patient.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/106,816 US7645459B2 (en) | 2004-05-24 | 2005-04-15 | Dosage forms of bisphosphonates |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29681B1 true MA29681B1 (fr) | 2008-08-01 |
Family
ID=36190430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30333A MA29681B1 (fr) | 2005-04-15 | 2007-10-29 | Formes galeniques du risedronate |
Country Status (16)
Country | Link |
---|---|
US (4) | US7645459B2 (fr) |
EP (1) | EP1868584A1 (fr) |
JP (1) | JP4788765B2 (fr) |
KR (2) | KR101070205B1 (fr) |
CN (2) | CN104027323A (fr) |
AU (1) | AU2005330654B2 (fr) |
BR (1) | BRPI0520082A2 (fr) |
CA (2) | CA2602188C (fr) |
IL (2) | IL186339A0 (fr) |
IN (1) | IN2012DN00827A (fr) |
MA (1) | MA29681B1 (fr) |
MX (1) | MX2007012821A (fr) |
NO (1) | NO20075834L (fr) |
RU (1) | RU2381791C2 (fr) |
SM (1) | SMAP200700047A (fr) |
WO (1) | WO2006112889A1 (fr) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563460B2 (en) * | 2004-02-26 | 2009-07-21 | Med Five, Inc. | Enteric coated oral pharmaceutical to erode kidney stones |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
EP1865928A1 (fr) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Compositions de biphosphanate nanoparticulaires |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
GB2430156A (en) * | 2005-09-16 | 2007-03-21 | Selamine Ltd | Bisphosphonate formulation |
US7201929B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
US7202229B1 (en) * | 2005-12-30 | 2007-04-10 | Alan James Group, Llc. | Aspirin formulation for cardiovascular health |
GB0616794D0 (en) * | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
AU2014201170B2 (en) * | 2006-12-20 | 2015-09-24 | Mylan Pharmaceuticals Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
WO2008074145A1 (fr) * | 2006-12-20 | 2008-06-26 | Genpharm Ulc | Composition pharmaceutique comprenant un lubrifiant granulé thermofusible |
WO2008153725A2 (fr) | 2007-05-25 | 2008-12-18 | North Carolina State University | Plate-forme pour l'apport, ciblé sur des cellules, de nanoparticules virales |
US8345282B2 (en) * | 2007-08-03 | 2013-01-01 | Kyocera Document Solutions Inc. | Image forming system and image forming apparatus |
WO2009018834A1 (fr) * | 2007-08-06 | 2009-02-12 | Pharmathen S.A. | Composition pharmaceutique contenant du biphosphonate et son procédé de préparation |
EP2255199A1 (fr) * | 2008-02-19 | 2010-12-01 | Jovesis Inc. | Compositions de microparticules pour modifier des cellules favorisant le cancer |
JP2011529902A (ja) * | 2008-07-31 | 2011-12-15 | 味の素株式会社 | リセドロネートまたはその塩の低投与量形態 |
SG171362A1 (en) * | 2008-11-20 | 2011-07-28 | Avantor Performance Mat Inc | Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient |
US8628812B2 (en) | 2008-12-30 | 2014-01-14 | Pepsico, Inc. | Preservative system for acidic beverages based on sequestrants |
TR200900878A2 (tr) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
SI2459176T1 (en) | 2009-07-31 | 2018-01-31 | Gruenenthal Gmbh | Crystallization process and bioavailability |
EP2458996B1 (fr) | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Nouvelles formes orales d'un dérivé d'acide phosphonique |
EP2493905B1 (fr) * | 2009-10-26 | 2016-11-30 | Warner Chilcott Company, LLC | Composés bisphosphonates destinés au traitement de troubles du métabolisme osseux |
FR2954320B1 (fr) | 2009-12-17 | 2012-06-15 | Cll Pharma | Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
FR2967576B1 (fr) * | 2010-11-18 | 2013-07-12 | Advicenne Pharma | Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
KR20120105738A (ko) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | 장용코팅된 경구용 제제 |
KR20140047617A (ko) * | 2011-06-23 | 2014-04-22 | 바이엘 뉴질랜드 리미티드 | 마크로사이클릭 락톤 및 레바미솔을 포함하는 항-기생충 조성물 및 기생충 감염의 치료 방법 |
CN102885759A (zh) * | 2011-07-20 | 2013-01-23 | 杭州赛利药物研究所有限公司 | 利塞膦酸钠延释制剂及其制备方法 |
KR101324425B1 (ko) * | 2011-07-22 | 2013-11-01 | 동아에스티 주식회사 | 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제 |
US10588857B2 (en) | 2012-03-29 | 2020-03-17 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
MX350569B (es) * | 2012-12-03 | 2017-09-11 | Landsteiner Scient S A De C V | Composicion farmaceutica estable para el tratamiento de osteoporosis. |
BR112015023124A2 (pt) | 2013-03-14 | 2017-07-18 | Therabiome Llc | liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal |
JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | Glp-1アゴニスト及び腸溶コーティングを含む錠剤 |
CN105267145B (zh) * | 2015-11-01 | 2019-06-21 | 袁旭东 | 双膦酸盐的自乳化配方和相关剂型 |
WO2017208070A1 (fr) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique |
BR112020019128A2 (pt) * | 2018-03-23 | 2021-01-12 | Palatin Technologies, Inc. | Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859A (en) * | 1848-10-17 | Improvement in cultivators | ||
FR2548530B1 (fr) | 1983-07-07 | 1986-10-24 | Hatte Louis | Perfectionnement aux chaises paillees |
US5167947A (en) | 1989-10-26 | 1992-12-01 | Southwest Research Institute | Enhancement of absorption of radioprotective drugs |
US5356887A (en) | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
CA2035179C (fr) | 1990-01-31 | 2001-08-14 | Gerald S. Brenner | Composition pharmaceutique contenant des sels insolubles d'acides biphosphonique |
ZA918168B (en) * | 1990-10-16 | 1993-04-14 | Takeda Chemical Industries Ltd | Prolonged release preparation and polymers thereof. |
FI89364C (fi) | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
CA2122479C (fr) | 1991-11-22 | 1998-08-25 | Richard John Dansereau | Compositions de risedronate a liberation retardee |
EP0550385A1 (fr) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Compositions pharmaceutiques orales contenant des dérivés d'acide méthane-diphosphonique et des éthers 18-couronne-6 |
SE501389C2 (sv) | 1992-04-24 | 1995-01-30 | Leiras Oy | Farmaceutiskt preparat och förfarande för dess framställning |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
CN1072964C (zh) * | 1994-04-22 | 2001-10-17 | 山之内制药株式会社 | 结肠特异性释药系统 |
US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
JPH089120A (ja) | 1994-06-21 | 1996-01-12 | Nec Corp | 画データ転送制御方法 |
JP3672342B2 (ja) | 1994-09-26 | 2005-07-20 | アステラス製薬株式会社 | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル |
US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
DE19615812A1 (de) * | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
US5853759A (en) | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
EP0939624B1 (fr) | 1996-05-17 | 2003-12-17 | Merck & Co., Inc. | Formulation de bisphosphonate efferverscente |
US5735810A (en) | 1996-06-14 | 1998-04-07 | Becton Dickinson And Company | Device for the iontophoretic administration of bisphosphonates |
PL332496A1 (en) | 1996-10-04 | 1999-09-13 | Merck & Co Inc | Liquid alendronate preparations |
US6410782B1 (en) | 1997-07-09 | 2002-06-25 | Geange Ltd. | Diphosphonic acid salts for the treatment of osteoporosis |
US6432932B1 (en) * | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US5994329A (en) | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
AU1525700A (en) | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
DE60005502T2 (de) * | 1999-05-12 | 2004-06-24 | Yamasa Corp., Choshi | 4'-c-ethynyl-purin-nukleoside |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
AU761343B2 (en) | 1999-06-30 | 2003-06-05 | Moo-Won Byun | Apparatus for producing multiple channel duct assembly and method thereof |
AR024462A1 (es) * | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
AU2127200A (en) | 1999-11-02 | 2001-05-14 | Cipla Limited | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof |
US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
CN1446093A (zh) | 2000-04-07 | 2003-10-01 | 得克萨斯系统大学董事会 | 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用 |
US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
CN1492763B (zh) * | 2001-03-01 | 2012-05-23 | 艾米斯菲尔技术有限公司 | 用于递送二膦酸盐的组合物 |
ITMI20011337A1 (it) | 2001-06-26 | 2002-12-26 | Farmatron Ltd | Composizioni farmaceutiche orali a rilascio modificato del principio attivo |
CA2454200A1 (fr) | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate |
WO2003051373A1 (fr) | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Formulations de bisphosphonate liquides pour troubles osseux |
US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
BR0106601A (pt) | 2001-12-21 | 2003-09-09 | Libbs Farmaceutica Ltda | Composição farmacêutica contendo bisfosfonato para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, seu uso na preparação de medicamento para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, método de tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato |
JP3869456B2 (ja) | 2003-01-17 | 2007-01-17 | テバ ファーマシューティカル インダストリーズ リミティド | 鉄含有量が非常に低いリセドロン酸ナトリウム |
CA2528519A1 (fr) | 2003-06-11 | 2005-02-24 | Novacea, Inc. | Traitement du cancer du poumon avec des composes de vitamine d actifs, en combinaison avec d'autres traitements |
US20050182028A1 (en) * | 2004-02-13 | 2005-08-18 | Chen Chih-Ming J. | Pharmaceutical formulation for oral delivery of bisphosphates |
US7785619B2 (en) * | 2004-04-08 | 2010-08-31 | Micro Nutrient, Llc | Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens |
CA2566798A1 (fr) * | 2004-05-24 | 2005-12-08 | The Procter & Gamble Company | Formes de posologies de diphosphonates |
US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20060069069A1 (en) * | 2004-07-15 | 2006-03-30 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses |
WO2006020009A1 (fr) | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Dosage oral solide formant un bisphosphonate et contenant un agent chélateur |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
EP1865928A1 (fr) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Compositions de biphosphanate nanoparticulaires |
US20070003512A1 (en) * | 2005-06-20 | 2007-01-04 | Stockel Richard F | Bisphosphonate resinates |
EP2007397B1 (fr) * | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Forme pharmaceutique solide par voie orale contenant un activateur |
-
2005
- 2005-04-15 US US11/106,816 patent/US7645459B2/en active Active
- 2005-11-23 RU RU2007136046/15A patent/RU2381791C2/ru active
- 2005-11-23 CN CN201410192870.3A patent/CN104027323A/zh active Pending
- 2005-11-23 CA CA002602188A patent/CA2602188C/fr active Active
- 2005-11-23 EP EP05852255A patent/EP1868584A1/fr not_active Ceased
- 2005-11-23 KR KR1020077023276A patent/KR101070205B1/ko active IP Right Grant
- 2005-11-23 KR KR1020107028875A patent/KR101280138B1/ko active IP Right Grant
- 2005-11-23 MX MX2007012821A patent/MX2007012821A/es active IP Right Grant
- 2005-11-23 AU AU2005330654A patent/AU2005330654B2/en not_active Withdrawn - After Issue
- 2005-11-23 CN CNA2005800494833A patent/CN101166519A/zh active Pending
- 2005-11-23 IN IN827DEN2012 patent/IN2012DN00827A/en unknown
- 2005-11-23 WO PCT/US2005/042887 patent/WO2006112889A1/fr active Application Filing
- 2005-11-23 SM SM200700047T patent/SMAP200700047A/it unknown
- 2005-11-23 BR BRPI0520082-2A patent/BRPI0520082A2/pt not_active Application Discontinuation
- 2005-11-23 JP JP2008506439A patent/JP4788765B2/ja not_active Expired - Fee Related
- 2005-11-23 CA CA002675652A patent/CA2675652A1/fr not_active Abandoned
-
2007
- 2007-10-07 IL IL186339A patent/IL186339A0/en unknown
- 2007-10-29 MA MA30333A patent/MA29681B1/fr unknown
- 2007-11-14 NO NO20075834A patent/NO20075834L/no not_active Application Discontinuation
-
2009
- 2009-12-14 US US12/637,100 patent/US8246989B2/en active Active
-
2012
- 2012-07-09 US US13/544,377 patent/US8535718B2/en active Active
-
2013
- 2013-08-12 US US13/964,359 patent/US20130331361A1/en not_active Abandoned
-
2019
- 2019-08-04 IL IL268462A patent/IL268462A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005330654B2 (en) | 2011-06-23 |
RU2381791C2 (ru) | 2010-02-20 |
JP2008535912A (ja) | 2008-09-04 |
CA2602188A1 (fr) | 2006-10-26 |
NO20075834L (no) | 2007-11-14 |
AU2005330654A1 (en) | 2006-10-26 |
CN101166519A (zh) | 2008-04-23 |
US20130012478A1 (en) | 2013-01-10 |
EP1868584A1 (fr) | 2007-12-26 |
SMP200700047B (it) | 2007-11-21 |
IN2012DN00827A (fr) | 2015-06-26 |
BRPI0520082A2 (pt) | 2009-04-14 |
US20130331361A1 (en) | 2013-12-12 |
KR101280138B1 (ko) | 2013-06-28 |
KR20070111551A (ko) | 2007-11-21 |
JP4788765B2 (ja) | 2011-10-05 |
SMAP200700047A (it) | 2007-11-21 |
IL186339A0 (en) | 2008-01-20 |
RU2007136046A (ru) | 2009-05-20 |
CN104027323A (zh) | 2014-09-10 |
MX2007012821A (es) | 2007-11-20 |
IL268462A (en) | 2019-09-26 |
US20100086593A1 (en) | 2010-04-08 |
CA2602188C (fr) | 2009-10-13 |
US8246989B2 (en) | 2012-08-21 |
CA2675652A1 (fr) | 2006-10-26 |
KR101070205B1 (ko) | 2011-10-06 |
US8535718B2 (en) | 2013-09-17 |
US7645459B2 (en) | 2010-01-12 |
US20050260262A1 (en) | 2005-11-24 |
KR20110002887A (ko) | 2011-01-10 |
WO2006112889A1 (fr) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29681B1 (fr) | Formes galeniques du risedronate | |
JP5749255B2 (ja) | L−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 | |
NO20065969L (no) | Doseringsformer for bifosfonater | |
MA32027B1 (fr) | Preparation de capsules | |
MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
MA27710A1 (fr) | Formulations pharmaceutiques liquides de palonosetrone | |
MA37471A1 (fr) | Formulation lyophilise et aqueuse d’anticorps anti-cd40 | |
EP2248519A3 (fr) | Formes galéniques de film non mucoadhésifs | |
ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
MA32347B1 (fr) | Gelule pour la prévention de maladies cardiovasculaires | |
WO2011151722A3 (fr) | Méthodes et compositions de traitement pharmaceutique par voie orale | |
MA45625A (fr) | Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl | |
RU2010151631A (ru) | Бисглицинат-хелат железа для использования в пероральном лечении анемии у пациентов с целиакией | |
ATE457721T1 (de) | An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen | |
AR083393A1 (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor | |
Kour et al. | Screening models of nephrotoxicity and their molecular mechanism | |
ES2440196T3 (es) | Nuevo uso de cloruro de amonio para la terapia de insuficiencia hepática total o parcial y necrosis | |
MY140503A (en) | Formulation of sec1 mutated protein and method for formulation of the same | |
A. Escobedo et al. | An old drug against giardiasis: mebendazole as a treatment option | |
RU2007129408A (ru) | Способ выращивания поросят в период откорма | |
RU2006132127A (ru) | Применение нифуроксазида в качестве компонента комбинированной лекарственной терапии заболеваний, ассоциированных с helicobacter pylori, и способ лечения, направленный на эрадикацию возбудителя | |
EA200700524A1 (ru) | Препараты для перорального применения с эффектом замедленного действия при приеме api вместе с пищей | |
Gupta et al. | Hepatoprotective activity of methanol extracts of Glinus oppositifolius and Trianthema decandra against paracetamol induced liver damage | |
FR3116439B1 (fr) | Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains | |
MA31744B1 (fr) | Compositions pharmaceutiques lyophilisees |